EN
ENLV.US Enlivex Therapeutics Ltd
- Market cap
- USD 1.82M
- P/E
- 0.0x
- P/B
- 0.00x
- ROE
- 147.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ENLV.US undervalued?
Graham numberThe Graham number of Enlivex Therapeutics Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enlivex Therapeutics Ltd fundamental analysis
No fundamental analysis for Enlivex Therapeutics Ltd yet.
Enlivex Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enlivex Therapeutics Ltd
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failur…
Full company profileEnlivex Therapeutics Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Enlivex Therapeutics Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 2.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -25.0K | -12.0K | -121K | -297K | -286K | -546K | -777K | -835K | -545K | -332K | - |
| Operating Income | -13.9M | -5.85M | -5.30M | -8.62M | -9.79M | -19.3M | -25.8M | -29.4M | -15.5M | -15.0M | -24.3M |
| EBITDA | -13.9M | -5.91M | -5.18M | -8.41M | -9.50M | -18.7M | -25.0M | -28.2M | -14.5M | -14.7M | -24.1M |
| Net Income | -16.0M | -5.95M | -4.24M | -9.38M | -11.8M | -14.5M | -31.1M | -29.1M | -15.0M | 1.24B | 5.73B |
| EPS | -9,669 | -3,332 | -2,208 | -260 | -215 | -194 | -405 | -376 | -176 | 6,114 | 4,744 |
| Balance Sheet | |||||||||||
| Total Assets | 10.6M | 3.62M | 11.0M | 17.6M | 40.4M | 95.1M | 67.6M | 36.8M | 27.7M | 2.33B | 4.90B |
| Total Liabilities | 1.93M | 460K | 1.33M | 6.28M | 4.87M | 10.1M | 10.8M | 6.75M | 4.10M | 392M | 1.00B |
| Shareholders' Equity | 8.70M | 3.16M | 9.71M | 11.3M | 35.5M | 85.0M | 56.8M | 30.1M | 23.6M | 1.93B | 3.90B |
| Cash & Short-term Investments | 9.88M | 3.53M | 9.78M | 12.0M | 35.7M | 84.1M | 50.2M | 27.3M | 23.6M | 5.87M | 5.52M |
| Total Debt | - | - | - | 123K | 203K | 6.01M | 4.85M | 1.03M | 534K | 641K | 17.2M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.5M | -6.35M | -3.16M | -7.04M | -11.0M | -17.5M | -24.0M | -23.5M | -13.0M | -10.4M | -21.9M |
| Capital Expenditure | 18.0K | 2.00K | 461K | 193K | 1.02M | 1.63M | 8.12M | 236K | 103K | 68.0K | 18.0K |
| Free Cash Flow | -15.5M | -6.35M | -3.62M | -7.23M | -12.0M | -19.2M | -32.1M | -23.8M | -13.1M | -10.5M | -21.9M |
| Ratios | |||||||||||
| ROE | -184.2% | -188.0% | -43.7% | -83.2% | -33.3% | -17.0% | -54.6% | -96.6% | -63.6% | 63.9% | 147.0% |
| ROA | -150.7% | -164.1% | -38.4% | -53.4% | -29.3% | -15.2% | -45.9% | -78.9% | -54.2% | 53.1% | 117.0% |
| Net Profit Margin | - | - | - | - | -519.3% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | 0.01x | 0.01x | 0.07x | 0.09x | 0.03x | 0.02x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Enlivex Therapeutics Ltd dividends
Enlivex Therapeutics Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:16 on Oct 27, 2026.
Who owns Enlivex Therapeutics Ltd
- Insiders 55.90%
- Institutions 1.71%
- Public & others 42.39%
- Shares outstanding 1.53M
- Free float 410K
Top funds holding ENLV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 8.66K | 0.05% | -0.01% | Jul 2026 |
Top institutions holding ENLV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ARK Investment Management LLC | 2.38M | 0.80% | +279.23% | Jun 2026 |
| Springbok Capital Management, LLC | 321K | 0.11% | +42.34% | Jun 2026 |
| Bank of America Corp | 193K | 0.06% | +48.12% | Jun 2026 |
| Two Sigma Investments LLC | 184K | 0.06% | +25.62% | Jun 2026 |
| Susquehanna International Group, LLP | 158K | 0.05% | +1,428.49% | Jun 2026 |
| Renaissance Technologies Corp | 134K | 0.04% | +4.45% | Jun 2026 |
| Geode Capital Management, LLC | 130K | 0.04% | +61.19% | Jun 2026 |
| JPMorgan Chase & Co | 121K | 0.04% | -3.69% | Jun 2026 |
| SIMPLEX TRADING, LLC | 111K | 0.04% | +4,160.27% | Jun 2026 |
| The Goldman Sachs Group Inc | 89.4K | 0.03% | -12.42% | Jun 2026 |
| UBS Group AG | 73.9K | 0.02% | -46.57% | Jun 2026 |
| HRT FINANCIAL LLC | 49.7K | 0.02% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 21.9K | 0.01% | -78.20% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 8.50K | 0.00% | -91.36% | Jun 2026 |
| MCGUIRE CAPITAL ADVISORS INC | 2.50K | 0.00% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 1.04K | 0.00% | +403.38% | Jun 2026 |
| Activest Wealth Management | 1.00K | 0.00% | 0.00% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 500.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 402.00 | 0.00% | -65.70% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 2.00 | 0.00% | +100.00% | Jun 2026 |
Enlivex Therapeutics Ltd company profile
- Company name
- Enlivex Therapeutics Ltd
- Ticker
- ENLV.US
- ISIN
- IL0011319527
- Exchange
- USA Stocks
- Listed since
- Dec 12, 1995
- Sector
- Healthcare
- Industry
- Software
- Employees
- 34
- Fiscal year end
- December
- Address
- 14 Einstein Street, Ness Ziona, Israel, 7403618
- Phone
- 972 2 620 8072
- Website
- enlivex.com
About Enlivex Therapeutics Ltd
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Enlivex Therapeutics Ltd management
7- Mr. Shai Novik M.B.A.Executive Chairman · born 1966
- Dr. Oren Hershkovitz Ph.D.Chief Executive Officer · born 1977
- Prof. Dror Mevorach M.D.Founder & Scientific Advisor · born 1956
- Ms. Shachar Shlosberger CPAChief Financial Officer · born 1977
- Dr. Veronique Amor-BaroukhChief Operating Officer
- Ms. Sigal AradDirector of Human Resources
- Dr. Einat Galamidi M.D.Chief Medical Officer · born 1974